Research & Development
BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test
The test uses a single nasal or nasopharyngeal swab sample to identify and distinguish whether a patient has COVID-19, the flu, RSV, or some combination of the three, with results available in two hours.
February 8, 2023
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
Imspex lands CE Mark for COVID-19 breath test
A breath analyzer based on a combination of gas chromatography and ion mobility spectrometry technologies, BreathSpec is designed for use in a point-of-care setting by clinicians and nontechnical users in diagnosing respiratory tract infections, with specific utility for COVID-19, according to the Wales-based vendor.
August 8, 2022
Qiagen expands QIAstat-Dx syndromic panel
QIAstat-Dx Rise is compatible with Qiagen's updated QIAstat-Dx respiratory SARS-CoV-2 panel, the QIAstat-Dx gastrointestinal panel 2, as well as future assays. It provides results in about one hour.
May 15, 2022
Applied BioCode receives EUA for SARS-CoV-2 combo assay
The assay can simultaneously detect and differentiate between SARS-CoV-2, influenza A with subtypes, and respiratory syncytial virus in nasopharyngeal swab specimens, the company said. The test is designed to assist physicians in evaluating patients with clinical signs and symptoms of respiratory infection.
December 16, 2021
PerkinElmer receives EUA for respiratory SARS-CoV-2 panel
Qualified laboratories can immediately begin using the RT-PCR test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs, and midturbinate swabs, the company said.
October 6, 2021
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
Quest Diagnostics offers suite of services for transplant patients and living donors
Lumos touts cost savings for point-of-care infection test
FebriDx is a finger-stick blood test that distinguishes bacterial from viral acute respiratory infections. The study, published September 30 in the Journal of Health Economics and Outcomes Research, found that FebriDx had a sensitivity of 95% to detect bacterial infections and a negative predictive value of 99% to rule out these infections.
October 6, 2021
Ortho launches IL-6 reagent pack
Conditions that can be targeted by the test include autoimmune disorders, sepsis, severe respiratory infections from COVID-19, and community-acquired pneumonia in critically ill patients.
July 22, 2021
Ink dries on Hologic's deal to buy Mobidiag
Mobidiag's product line includes molecular diagnostic instruments and tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections, according to a release.
June 16, 2021
Hologic acquires Mobidiag for $795M
The deal includes a cash payment of approximately $714 million for Mobidiag's equity and net debt of approximately $81 million.
April 7, 2021
Qiagen secures EUA for COVID-19 test
NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.
March 28, 2021
FDA authorizes Quest's combined COVID-19 and flu RT-PCR test
The kit is available for prescription use with Quest's Self-Collection Kit for COVID-190 + Flu by individuals suspected to have respiratory viral infection consistent with COVID-19 when their healthcare provider deems home collection to be appropriate, according to the FDA. After collecting their sample at home, patients can ship it to a Quest laboratory for analysis.
December 7, 2020
Page 1 of 3